Kimball Electronics is in the middle of a rebrand and a rebuying cycle at once. The company closed its largest acquisition ever in early July of 2026, bought the Dutch microfluidics contract manufacturer Helvoet Polymer Technologies, and is asking shareholders at its November annual meeting to rename the company Kimball Solutions, Inc. and change the ticker from KE to KMBL. The strategic intent is clear: stop being an electronics manufacturing services firm that happens to make medical parts and become a true global medical CDMO platform. The operating story behind that move is real but narrow. Medical sales grew in fiscal 2026 while the automotive base lost a major program and tariffs kept North American demand soft, so the company is trying to grow its way out of an automotive trough by buying its way into a faster market.
The Helvoet deal is the event that changes the company. The purchase price of roughly $103 million was funded partly with cash and partly with borrowings on the existing credit lines. It represents about 9 times Helvoet's estimated adjusted EBITDA for calendar 2026. Management says the deal is expected to be accretive to fiscal 2027 adjusted earnings and to lift Kimball's medical vertical sales by a low double-digit percentage. Helvoet brings manufacturing in the Netherlands and India, a blue-chip medical customer base that overlaps with Kimball's, and a position in microfluidics, diagnostics, and drug delivery that Kimball's core electronics shop floor does not serve. The mechanism is straightforward. A smaller, older EMS base with flat revenue and a shrinking customer count buys a higher-multiple, higher-growth niche asset and uses its balance sheet to fund it. That is a reasonable use of cash if the integration works and the medical customers actually expand, but it is a real bet if either of those assumptions is wrong.
The tension is that the stock has already moved to price in a lot of the pivot. The shares trade around $25, a market cap near $600 million. Against a trailing EBITDA figure near $95 million, the multiple is not cheap. The company just sold its Tampa property for a $15 million gain, which flattered fiscal 2026 net income, and the effective tax rate jumped to a level that is unlikely to repeat. Open orders are flat year over year, and the customer count has fallen over two years. The market is paying a multiple that already reflects some medical growth, some margin recovery in Europe, and some execution on the new Indianapolis facility. That leaves less room for the thesis to be right in the way the rebrand suggests, and more room for the integration to disappoint.
The catalysts to watch are the November 13 name change vote, the fiscal 2027 first-quarter print that begins to include Helvoet, and the ramp of the new Indianapolis medical CDMO facility. If the stock is to re-rate meaningfully, it needs medical vertical growth that clearly exceeds the legacy base, a demonstrated ability to retain Helvoet's core personnel and customer relationships across three jurisdictions, and evidence that the Indianapolis ramp does not keep dragging down gross margin. If any of those three fail, the multiple has a long way to fall.